Zacks Investment Research
04 Nov 2026, 16:40 UTC · 1h ago
Impact · against what's priced in
Teva's stock is supported by strong growth in its innovative drug portfolio, particularly Austedo, which is offsetting a sharp decline in U.S. generic revenues. While the earnings beat is positive, the accelerating erosion of Revlimid generics highlights a structural shift in the company's revenue mix.
No priced-in read yet
What the story claims
4 claims · scored −1 bearish … +1 bullish · 4 new · 0 priced in
Teva reported Q3 2026 adjusted earnings of 86 cents per share, beating the Zacks Consensus Estimate of 72 cents.
Newreported November 04, 2026
So whatThe 19% earnings beat suggests a higher baseline for FY2026 EPS estimates.
More positive than 92% of claims this week
Austedo U.S. sales rose 21% year over year to $727 million, surpassing the Zacks Consensus Estimate of $674 million.
Continue reading
5 related stories
The 19% beat on adjusted earnings (86 cents vs 72 cents estimate) and 21% growth in Austedo sales provide a strong hedge against the 39% decline in U.S. generic/biosimilar revenues.
Read from the article alone
No priced-in read yet
The mention of increased competition for Revlimid contributing to Teva's generic revenue decline confirms ongoing market share erosion for BMY's key asset.
Read from the article alone
Scored by the NIS engine · methodology.
Newreported November 04, 2026
So whatWith 18% prescription growth, this key branded asset provides a hedge against generic erosion into 2027.
More positive than 84% of claims this week
Generic/biosimilar product revenues in the U.S. declined 39% year over year to $718 million, missing the Zacks Consensus Estimate of $799 million.
Newreported November 04, 2026
So whatThe $81 million miss relative to estimates highlights the accelerating impact of Revlimid competition.
More negative than 87% of claims this week
Q3 revenues were $4.40 billion, beating the Zacks Consensus Estimate of $4.24 billion.
Newreported November 04, 2026
So whatDespite the beat, total revenues fell 2% year-over-year, signaling a shift in the company's revenue mix.
More positive than 60% of claims this week
Which stocks this story touches
More positive than 71% of ticker scores this week
Reported Q3 earnings and revenues that beat Zacks Consensus Estimates, driven by strong innovative drug sales.
More negative than 71% of ticker scores this week
Mentioned in the context of increased competition for its drug Revlimid, contributing to revenue declines for competitors.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Seeking Alpha
56m ago
+2.6%
Price is moving against the score
$63.29 vs $61.71 close before publication (Nov 3) · not market-adjusted
BMY chart →+1.3%
Price agrees with the score
$42.47 vs $41.91 close before publication (Nov 3) · not market-adjusted
TEVA chart →
